/
Immunology
Systemic Lupus Erythematosus
126
Pipeline Programs↗
167
Active Trials↗
97
Companies Involved↗
Systemic Lupus Erythematosus is a highly competitive landscape with 126 programs across 97 companies. The most active players are AstraZeneca, Novartis, Bristol-Myers Squibb. 17 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical28
Phase 149
Phase 232
Phase 317
Approved
No programs
Analysis
Modality Breakdown
70%
Small molecule
71 of 102 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 102 classified programs, each share of the total. Modality classified for 92% of 126 pipeline programs.
Analysis
Trial Status
440
clinical trials
Completed184 · 42%
Recruiting92 · 21%
Terminated42 · 10%
Active, not recruiting36 · 8%
Not yet recruiting35 · 8%
Unknown status29 · 7%
Other22 · 5%
Clinical Trials
Trial Activity
440 trials
Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE)
Recruiting·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·N/A·NCT00001372·2,000 enrolled
Page 1 of 30
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)